China-based Ascletis Pharma Inc (HKEX code: 1672) has received approval from the National Medical Products Administration (NMPA) for its all-oral Hepatitis C virus (HCV) treatment, for marketing in China, it was reported on Thursday.
The all-oral HCV treatment is Ravidasvir (Asclevir) in combination with Danoprevir (Ganovo).
The company's phase II/III clinical trial has indicated that the treatment regimen showed a 99% cure rate with a short treatment duration of 12 weeks in genotype one patients, and in patients with baseline NS5A resistance mutations, the treatment Regimen indicated a cure rate of 100% (SVR12). National Science and Technology Major Project has chosen both Ravidasvir and Danoprevir for 'Innovative Drug Development' programs. Presidio Pharmaceuticals Inc, a clinical stage pharmaceutical company, licensed Ravidasvir.
More Than 13% of Northwell Health Care Providers Test Positive for Antibodies
CTI BioPharma reports six months ended 30 June 2020 financial results
PreveCeutical to begin clinical trials of cannabinoid Sol-Gel under the COVID-19 programme
Celularity awarded USD750,000 CIRM grant to advance COVID-19 treatment in California
Johnson & Johnson to supply 100m doses of investigational COVID-19 vaccine to the US Government
IMV Receives Canadian Government Funding for COVID-19 Vaccine Phase 1 Clinical Study